Chlamydophila pneumoniae in human immortal Jurkat cells and primary lymphocytes uncontrolled by interferon-γ

Microbes and Infection

Volumn 15, Issue 3, 2013, Pages 192-200

  Ishida, Kasumi ^a   Kubo, Takeru ^a   Saeki, Ayumi ^a   Yamane, Chikayo ^a   Matsuo, Junji ^a   Yimin, ^b   Nakamura, Shinji ^c   Hayashi, Yasuhiro ^a   Kunichika, Miyuki ^c   Yoshida, Mitsutaka ^c   Takahashi, Kaori ^c   Hirai, Itaru ^d   Yamamoto, Yoshimasa ^d,e   Shibata, Ken ichiro ^a   Yamaguchi, Hiroyuki ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c JUNTENDO UNIVERSITY   (Japan)

^d OSAKA UNIVERSITY   (Japan)

^e OSAKA PREFECTURAL INSTITUTE OF PUBLIC HEALTH   (Japan)

Author keywords

Chlamydophila pneumoniae; Indoleamine 2,3 dioxygenase; Interferon ; Lymphocytes

Indexed keywords

GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR 1; INDOLEAMINE 2,3 DIOXYGENASE; IONOMYCIN; PHORBOL MYRISTATE;

ANIMAL CELL; ARTICLE; BACTERIAL GROWTH; CELL IMMORTALIZATION; CELL STIMULATION; CHLAMYDOPHILA PNEUMONIAE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; INNATE IMMUNITY; KNOCKOUT MOUSE; LEUKEMIA CELL LINE; LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLEEN CELL; WESTERN BLOTTING; WILD TYPE;

ANIMALS; CHLAMYDOPHILA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; FEMALE; HELA CELLS; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERFERON-GAMMA; JURKAT CELLS; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROBIAL VIABILITY; RECEPTORS, INTERFERON; SPLEEN;

CHLAMYDIAE; CHLAMYDOPHILA PNEUMONIAE; MUS;

EID: 84874954458     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2012.11.006     Document Type: Article

References (40)

1. Rockey D.D., Matsumoto A. The chlamydial developmental cycle. Prokaryotic Development 2000, 403-425. ASM Press, Washington DC. Y.V. Brun, L.L. Shimkets (Eds.).
2. Bartlett J.G. Is activity against " atypical" pathogens necessary in the treatment protocols for community-acquired pneumonia? Issues with combination therapy. Clin. Infect. Dis. 2008, 47:S232-S236.
3. Blasi F., Tarsia P., Aliberti S. Chlamydophila pneumoniae. Clin. Microbiol. Infect. 2009, 15:29-35.
4. Watson C., Alp N.J. Role of Chlamydia pneumoniae in atherosclerosis. Clin. Sci. (Lond) 2008, 114:509-531.
5. Sessa R., Nicoletti M., Di Pietro M., Schiavoni G., Santino I., Zagaglia C., Del Piano M., Cipriani P. Chlamydia pneumoniae and atherosclerosis: current state and future prospectives. Int. J. Immunopathol. Pharmacol. 2009, 22:9-14.
6. Shima K., Kuhlenbäumer G., Rupp J. Chlamydia pneumoniae infection and Alzheimer's disease: a connection to remember?. Med. Microbiol. Immunol. 2010, 199:283-289.
7. Hu V.H., Harding-Esch E.M., Burton M.J., Bailey R.L., Kadimpeul J., Mabey D.C. Epidemiology and control of trachoma: systematic review. Trop. Med. Int. Health 2010, 15:673-691.
8. Da Ros C.T., Schmitt Cda S. Global epidemiology of sexually transmitted diseases. Asian J. Androl. 2008, 10:110-114.
9. Caldwell H.D., Wood H., Crane D., Bailey R., Jones R.B., Mabey D., Maclean I., Mohammed Z., Peeling R., Roshick C., Schachter J., Solomon A.W., Stamm W.E., Suchland R.J., Taylor L., West S.K., Quinn T.C., Belland R.J., McClarty G. Polymorphisms in Chlamydia trachomatis tryptophan synthase genes differentiate between genital and ocular isolates. J. Clin. Invest. 2003, 111:1757-1769.
10. Mehta S.J., Miller R.D., Ramirez J.A., Summersgill J.T. Inhibition of Chlamydia pneumoniae replication in HEp-2 cells by interferon-gamma: role of tryptophan catabolism. J. Infect. Dis. 1998, 177:1326-1331.
11. McClarty G., Caldwell H.D., Nelson D.E. Chlamydial interferon gamma immune evasion influences infection tropism. Curr. Opin. Microbiol. 2007, 10:47-51.
12. Nelson D.E., Virok D.P., Wood H., Roshick C., Johnson R.M., Whitmire W.M., Crane D.D., Steele-Mortimer O., Kari L., McClarty G., Caldwell H.D. Chlamydial IFN-gamma immune evasion is linked to host infection tropism. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:10658-10663.
13. Mannonen L., Nikula T., Haveri A., Reinikainen A., Vuola J.M., Lahesmaa R., Puolakkainen M. Up-regulation of host cell genes during interferon-gamma-induced persistent Chlamydia pneumoniae infection in HL cells. J. Infect. Dis. 2007, 195:212-219.
14. Belland R.J., Nelson D.E., Virok D., Crane D.D., Hogan D., Sturdevant D., Beatty W.L., Caldwell H.D. Transcriptome analysis of chlamydial growth during IFN-gamma-mediated persistence and reactivation. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:15971-15976.
15. Cook P.J., Honeybourne D. Clinical aspects of Chlamydia pneumoniae infection. Presse Med. 1995, 24:278-282.
16. Kobayashi M., Ishida K., Matsuo J., Nakamura S., Nagasawa A., Motohashi K., Yao T., Hirai I., Yamamoto Y., Suzuki H., Shimizu C., Matsuno K., Yamaguchi H. Chlamydophila pneumoniae attachment and infection in low proteoglycan expressing human lymphoid Jurkat cells. Microb. Pathog. 2011, 51:209-216.
17. Kubo T., Ishida K., Matsuo J., Nakamura S., Hayashi Y., Sakai H., Yoshida M., Takahashi K., Hirai I., Yamamoto Y., Yamaguchi H. Chlamydia trachomatis serovar L2 infection model using human lymphoid Jurkat cells. Microb. Pathog. 2012, 53:1-11.
18. Haranaga S., Yamaguchi H., Friedman H., Izumi S., Yamamoto Y. Chlamydia pneumoniae infects and multiplies in lymphocytes in vitro. Infect. Immun. 2001, 69:7753-7759.
19. Haranaga S., Yamaguchi H., Leparc G.F., Friedman H., Yamamoto Y. Detection of Chlamydia pneumoniae antigenin PBMNCs of healthy blood donors. Transfusion 2001, 41:1114-1119.
20. Yamaguchi H., Yamada M., Uruma T., Kanamori M., Goto H., Yamamoto Y., Kamiya S. Prevalence of viable Chlamydia pneumoniae in peripheral blood mononuclear cells of healthy blood donors. Transfusion 2004, 44:1072-1078.
21. Prasanna S.J., Gopalakrishnan D., Shankar S.R., Vasandan A.B. Pro-inflammatory cytokines, IFNγ and TNFα, influence immune properties of human bone marrow and Wharton jelly mesenchymal stem cells differentially. PLoS One 2010, 5:e9016.
22. Habibi D., Jalili R.B., Forouzandeh F., Ong C.J., Ghahary A. High expression of IMPACT protein promotes resistance to indoleamine 2,3-dioxygenase-induced cell death. J. Cell. Physiol. 2010, 225:196-205.
23. Haranaga S., Ikejima H., Yamaguchi H., Friedman H., Yamamoto Y. Analysis of Chlamydia pneumoniae growth in cells by reverse transcription-PCR targeted to bacterial gene transcripts. Clin. Diagn. Lab. Immunol. 2002, 9:313-319.
24. Ersvaer E., Skavland J., Ulvestad E., Gjertsen B.T., Bruserud Ø. Effects of interferon gamma on native human acute myelogenous leukaemia cells. Cancer Immunol. Immunother. 2007, 56:13-24.
25. Wu L., Bijian K., Shen S.H. CD45 recruits adapter protein DOK-1 and negatively regulates JAK-STAT signaling in hematopoietic cells. Mol. Immunol. 2009, 46:2167-2177.
26. Bernabei P., Coccia E.M., Rigamonti L., Bosticardo M., Forni G., Pestka S., Krause C.D., Battistini A., Novelli F. Interferon-gamma receptor 2 expression as the deciding factor in human T, B, and myeloid cell proliferation or death. J. Leukoc. Biol. 2001, 70:950-960.
27. Boselli D., Ragimbeau J., Orlando L., Cappello P., Capello M., Ambrogio C., Chiarle R., Marsili G., Battistini A., Giovarelli M., Pellegrini S., Novelli F. Expression of IFNγR2 mutated in a dileucine internalization motif reinstates IFNγ signaling and apoptosis in human T lymphocytes. Immunol. Lett. 2010, 134:17-25.
28. Regis G., Conti L., Boselli D., Novelli F. IFNgammaR2 trafficking tunes IFNgamma-STAT1 signaling in T lymphocytes. Trends Immunol. 2006, 96-101.
29. Carabeo R.A., Mead D.J., Hackstadt T. Golgi-dependent transport of cholesterol to the Chlamydia trachomatis inclusion. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:6771-6776.
30. Hackstadt T., Rockey D.D., Heinzen R.A., Scidmore M.A. Chlamydia trachomatis interrupts an exocytic pathway to acquire endogenously synthesized sphingomyelin in transit from the Golgi apparatus to the plasma membrane. EMBO J. 1996, 15:964-977.
31. Hackstadt T., Scidmore M.A., Rockey D.D. Lipid metabolism in Chlamydia trachomatis-infected cells: directed trafficking of Golgi-derived sphingolipids to the chlamydial inclusion. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:4877-4881.
32. Robertson D.K., Gu L., Rowe R.K., Beatty W.L. Inclusion biogenesis and reactivation of persistent Chlamydia trachomatis requires host cell sphingolipid biosynthesis. PLoS Pathog. 2009, 5:e1000664.
33. Takikawa O., Kuroiwa T., Yamazaki F., Kido R. Mechanism of interferon-gamma action. Characterization of indoleamine 2,3-dioxygenase in cultured human cells induced by interferon-gamma and evaluation of the enzyme-mediated tryptophan degradation in its anticellular activity. J. Biol. Chem. 1988, 263:2041-2048.
34. Ozaki Y., Edelstein M.P., Duch D.S. Induction of indoleamine 2,3-dioxygenase: a mechanism of the antitumor activity of interferon gamma. Proc. Natl. Acad. Sci. U. S. A. 1988, 85:1242-1246.
35. Haranaga S., Yamaguchi H., Ikejima H., Friedman H., Yamamoto Y. Chlamydia pneumoniae infection of alveolar macrophages: a model. J. Infect. Dis. 2003, 187:1107-1115.
36. Taylor M.W., Feng G.S. Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J. 1991, 5:2516-2522.
37. Du M.X., Sotero-Esteva W.D., Taylor M.W. Analysis of transcription factors regulating induction of indoleamine 2,3-dioxygenase by IFN-gamma. J. Interf. Cytokine Res 2000, 20:133-142.
38. Tietzel I., El-Haibi C., Carabeo R.A. Human guanylate binding proteins potentiate the anti-chlamydia effects of interferon-gamma. PLoS One 2009, 4:e6499.
39. Igietseme J.U., He Q., Joseph K., Eko F.O., Lyn D., Ananaba G., Campbell A., Bandea C., Black C.M. Role of T lymphocytes in the pathogenesis of Chlamydia disease. J. Infect. Dis. 2009, 200:926-934.
40. Van Voorhis W.C., Barrett L.K., Sweeney Y.T., Kuo C.C., Patton D.L. Analysis of lymphocyte phenotype and cytokine activity in the inflammatory infiltrates of the upper genital tract of female macaques infected with Chlamydia trachomatis. J. Infect. Dis. 1996, 174:647-650.